The content for this activity is based on the satellite symposium, “Applying Recent Advances in the Science of CFTR-based Therapeutics to Improve Outcomes in Patients With Cystic Fibrosis”, that was presented at the 30th Annual North American Cystic Fibrosis Conference in Orlando, Florida on October 28, 2016. The content highlights the latest advancements, particularly in CFTR-based therapeutics, for the treatment of patients with cystic fibrosis. Expert faculty discuss the most up-to-date analysis for clinical decision-making, including updates on assessment, monitoring, and management of patients treated with CFTR modulator therapies. The goal of this activity is to increase the knowledge and competencies of the multidisciplinary team involved in the management of patients with CF, and provide strategies for improving the lives of patients. Upon completion of this activity, healthcare providers will be better equipped with imperative information for creating more effective personalized treatment plans and improving patient outcomes.
This activity is designed for physicians, nurses, and other healthcare professionals involved in the management of patients with cystic fibrosis.
Upon completion of this activity, participants will be better able to do the following:
- Review and analyze the current clinical trial data for CFTR modulator therapeutics to develop effective individualized treatment plans.
- Indicate the details of real-world outcomes for patients treated with CFTR-based therapeutics.
- Apply the principles of early diagnosis and early pharmaco-therapeutic intervention to the pediatric cystic fibrosis population.
- Understand the science of developing therapeutic options for treating a larger population of cystic fibrosis patients.
JP Clancy, MD
Professor and Gunnar Esiason/Cincinnati Bell Chair
Director, Pulmonary Medicine Research
Medical Director, Office of Clinical and Translational Research
Cincinnati Children’s Hospital Medical Center
Debbie S. Benitez, RN, MSN, ACNP-BC
Pulmonary Nurse Practitioner/Nurse Coordinator
Center for Cystic Fibrosis
Keck Medical Center of USC
Los Angeles, California
Isabelle Fajac, MD, PhD
Professor of Physiology
Head of the Respiratory Physiology Unit
Adult CF Center
Sorbonne Paris Cité University
Manu Jain, MD, MS
Professor of Medicine & Pediatrics
Director of Adult CF
Feinberg School of Medicine
Steven M. Rowe, MD, MSPH
Professor, Department of Medicine, Pediatrics, and Cell Developmental & Integrative Biology
Director, Gregory Fleming James
Cystic Fibrosis Research Center
Gwaltney Endowed Chair Medical Research
University of Alabama at Birmingham
Gregory Sawicki, MD, MPH
Director, Cystic Fibrosis Center
Boston Children’s Hospital
Assistant Professor of Pediatrics
Harvard Medical School
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|JP Clancy, MD|
Consultant/Advisor: Nivalis Therapeutics
Grant/Research Support: Bayer AG; Nivalis Therapeutics; ProQR Therapeutics; Vertex Pharmaceuticals Incorporated
Speakers Bureau: Genentech, Inc.
Debbie S. Benitez, RN, MSN, ACNP-BC
Consultant/Advisor: Genentech, Inc.; Vertex Pharmaceuticals Incorporated
Speakers Bureau: Gilead
|Isabelle Fajac, MD, PhD|
Consultant/Advisor: Bayer AG; EPG Health Media; Galapagos NV; Novartis AG; Vertex Pharmaceuticals Incorporated
Grant/Research Support: Bayer AG; Novartis AG; Vertex Pharmaceuticals IncorporatedSpeakers Bureau: Vertex Pharmaceuticals Incorporated
|Manu Jain, MD|
Consultant/Advisor: Gilead; Vertex Pharmaceuticals IncorporatedSpeakers Bureau: Gilead; Vertex Pharmaceuticals Incorporated
|Steven M. Rowe, MD|
Consultant/Advisor: Novartis AG; PTC Therapeutics; Raptor Pharmaceuticals; Synedgen; Vertex Pharmaceuticals Incorporated
Grant/Research Support: AstraZeneca; Novartis AG; PTC Therapeutics; Shire; Synedgen; Vertex Pharmaceuticals Incorporated
|Gregory Sawicki, MD, MPH|
Consultant/Advisor: Genentech, Inc.; Gilead; Novartis AG; Vertex Pharmaceuticals Incorporated
Grant/Research Support: Vertex Pharmaceuticals IncorporatedRoyalties/Patents: UpToDate, Inc.
Non-faculty: Timothy Hayes, MD, PhD; Emma Gilmartin; Nicole Brestowski; Chelsey Benedek; Eileen S Robinson MSN, RN; Sandy Breslow; Alison Kemp; Leah Johnson; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
This CME activity has been peer-reviewed by The Journal of Cystic Fibrosis.
This CME activity has been supported by an independent educational grant from Vertex Pharmaceuticals Incorporated.
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.
CME Credit (Physicians)
The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses)
Elsevier is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Elsevier is provider approved by the Florida Board of Nursing, Provider #50-4681, and the California Board of Registered Nursing, Provider #CEP 3257.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the EOCME, Elsevier accredited Provider Unit, and AcademicCME. The EOCME is accredited by the ACCME to provide continuing medical education for physicians. Elsevier’s Provider Unit is accredited by ANCC COA to provide continuing nursing education.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME, and Vertex Pharmaceuticals Incorporated do not recommend the use of any agent outside of the labeled indications.
Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.